On December 6, 2023, Glonghui announced that on December 6, 2024, the company (as a limited partner), Guojian Jinqian (as the general partner and executive partner), and Baojing (as a limited partner) entered into a limited partnership agreement to establish a limited partnership in china. According to the limited partnership agreement, (i) the total capital contribution of the limited partnership will be RMB 54.3 million, with Guojian Jinqian, the company, and Baojing contributing RMB 0.01 million, RMB 32.8 million, and RMB 21.49 million respectively, accounting for approximately 0.0184%, 60.4052%, and 39.5764% of the total contributions. This limited partnership will not be accounted for as a subsidiary of the company, and its financial performance will not be consolidated into the group's comprehensive financial statements.

The name of the limited partnership: Peking Yichuang Xin'an Technology Development Center (Limited Partnership). The business scope of the limited partnership includes technology development, technology promotion, technology transfer, technology consulting, technology services, corporate management, corporate management consulting, health consulting services (excluding diagnostic and treatment services), and medical research and experimental development (excluding the development and application of human stem cells, gene diagnosis, and treatment technologies).

Establishing a limited partnership is a good opportunity for the group's investment portfolio diversification. Directors believe that through strategic cooperation and resource sharing with other partners in the form of a limited partnership, the group will be able to invest in high-quality investment targets, thereby establishing a system composed of entities and personnel with different capital resources, expertise, and technical knowledge, seizing potential investment opportunities, and promoting the group's economic benefits, expanding business scale, and maximizing profitability.